

Clinical trials of embolic protection for atrial fibrillation in all type of patients

TrialResults-center www.trialresultscenter.org

1 LLA closure

Trial	Treatments	Patients	Trials design and methods
Watchman vs warfarin			
PROTECT-AF [NCT00129545] n=463/244 follow-up: 900 patients-year	closure of the left atrial appendage(LAA) using the Watchman device versus long-term warfarin therapy	patients with documented nonvalvular atrial fibrillation who could take long-term warfarin, but without any indication that would require warfarin	Parallel groups open US, Europe

References

PROTECT-AF, :

Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S Safety of Percutaneous Left Atrial Appendage Closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry. *Circulation* 2011 Jan 17;: [21242484] [10.1161/CIRCULATIONAHA.110.976449](https://doi.org/10.1161/CIRCULATIONAHA.110.976449)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.